Lecithin cholesterol acyltransferase deficiency
| Lecithin–cholesterol acyltransferase deficiency | |
|---|---|
| Synonyms | LCAT deficiency |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Corneal opacities, anemia, kidney failure |
| Complications | Renal failure, cardiovascular disease |
| Onset | Childhood or early adulthood |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation in the LCAT gene |
| Risks | Family history of the condition |
| Diagnosis | Blood test, genetic testing |
| Differential diagnosis | Fish-eye disease, familial hypercholesterolemia |
| Prevention | N/A |
| Treatment | Symptomatic treatment, kidney transplant |
| Medication | None specific |
| Prognosis | Variable, depends on severity and management |
| Frequency | Rare |
| Deaths | N/A |
Lecithin cholesterol acyltransferase deficiency (LCAT deficiency) is a rare genetic disorder characterized by the body's inability to properly metabolize certain fats (lipids) in the blood. The condition is caused by mutations in the LCAT gene and is inherited in an autosomal recessive manner.
Symptoms[edit]
The symptoms of LCAT deficiency can vary greatly from person to person. Some affected individuals may have no symptoms (asymptomatic) while others may develop serious complications. The most common symptoms include:
Causes[edit]
LCAT deficiency is caused by mutations in the LCAT gene. This gene provides instructions for making an enzyme called lecithin cholesterol acyltransferase, which is found in the blood and is involved in the metabolism of lipids. Mutations in the LCAT gene reduce or eliminate the activity of this enzyme, leading to the characteristic features of LCAT deficiency.
Diagnosis[edit]
The diagnosis of LCAT deficiency is based on a clinical evaluation, detailed patient history, and specialized laboratory testing. Genetic testing can confirm a diagnosis.
Treatment[edit]
There is currently no cure for LCAT deficiency. Treatment is directed toward the specific symptoms that are apparent in each individual. For example, individuals with kidney disease may require dialysis or a kidney transplant.
See also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


